Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Kodiak Sciences Inc.

KOD ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$32.85

▲ +0.24%

Market Cap $2.06B · Vol 283.73K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.06B

Mid Cap

Div Yield

N/A

EPS Growth

+7.69%

YoY

RSI (14)

10.06

Momentum

Beta

2.25

vs Market

52W High

$47.55

31.08% below

52W Low

$9.22

257.36% above

Volume

283.73K

Avg 219.57K

P/B

10.97

Price-to-book

ROE

-149.49%

Return on equity

Free Float

94.84%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Kodiak Sciences Inc. (KOD) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KOD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.06%

-19.84%

-8.01%

+37.74%

YTD

+17.49%

+256.68%

+1,413.82%

-68.03%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-229,967,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-149.49%
ROA · ROIC	-66.94% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	10.97
P/FCF	N/A
EPS Growth	+7.69%
Outstanding Shares	62.85M

Technical Indicators

50-Day SMA	$39.52
200-Day SMA	$33.62
RSI (14)	10.06
Beta	2.25
52-Week High	$47.55
52-Week Low	$9.22

Volume Today	283.73K
Avg Daily Volume (30D)	219.57K
Relative Volume	1.29x
Volatility (10D)	24.11
Volatility (30D)	43.36
Free Float	94.84%

Analyst Consensus

BUY

Current Price $32.85

Mean Target $69.75

52W Low$9.22 52W High$47.55

Current

Target

$9.22 $47.55

Current Analyst target

+112.33% upside potential · 5 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00BVR0D11

ISINUS50015M1099

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeUNT Unit

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.49% ARGX.BR argenx SE +2.29% ARGX argenx SE +1.13% INSM Insmed Incorporated +1.14% 2269.HK WuXi Biologics (Cayman) Inc. +0.32%

Company Profile

Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.